Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337250 | 0.93 | TSHR (0.36) | PARP1KDM4EHSD17B10 | |
| SCHEMBL17337253 | 0.93 | TSHR (0.36) | PARP1KDM4EHSD17B10 | |
| SCHEMBL17337353 | 0.88 | PRKCB (0.33) | PARP1 | |
| SCHEMBL17337350 | 0.88 | PRKCB (0.33) | PARP1 | |
| SCHEMBL23130019 | 0.88 | PARP1 (0.36) | PARP1HSD17B10 | |
| SCHEMBL17347850 | 0.88 | PARP1 (0.36) | PARP1HSD17B10 | |
| SCHEMBL17337284 | 0.87 | TSHR (0.40) | PARP1KDM4EHSD17B10 | |
| SCHEMBL17337280 | 0.87 | TSHR (0.40) | PARP1KDM4EHSD17B10 | |
| SCHEMBL19228054 | 0.86 | KDM4E (0.31) | KDM4EHSD17B10 | |
| SCHEMBL23837473 | 0.85 | PARP1 (0.33) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226135-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | PARP1 589/4885KDM4E 720/4885HSD17B10 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.